Siren, L.L.C. Bei Gene, Ltd. Transaction History
Siren, L.L.C.
- $1.76 Trillion
- Q1 2025
A detailed history of Siren, L.L.C. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Siren, L.L.C. holds 498,689 shares of BGNE stock, worth $113 Million. This represents 7.73% of its overall portfolio holdings.
Number of Shares
498,689
Previous 653,721
23.72%
Holding current value
$113 Million
Previous $121 Billion
12.41%
% of portfolio
7.73%
Previous 5.33%
Shares
3 transactions
Others Institutions Holding BGNE
# of Institutions
286Shares Held
36.2MCall Options Held
111KPut Options Held
112K-
Baker Bros. Advisors LP New York, NY8.8MShares$1.99 Billion23.78% of portfolio
-
Capital International Investors Los Angeles, CA5.09MShares$1.15 Billion0.24% of portfolio
-
Primecap Management CO Pasadena, CA5.09MShares$1.15 Billion0.94% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.71MShares$615 Million0.09% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E91.03MShares$234 Million7.2% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...